Posted on

cbd isolated 99.14 pure cbd

Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia 2016; 57: 1617-24.

Sands, T. T. Rahdari, S. Oldham, M. S. Caminha Nunes, E. Tilton, N. Cilio, M. R. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. CNS Drugs 2019; 33:47-60:

Other studies

Thiele E, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 2018. doi: 10.1016/S0140-6736(18)30136-3.[Epub ahead of print 24 Jan 2018].

The use of cannabidiol (CBD) for treatment of pharmacoresistant epilepsies is increasing. CBD is metabolized via UDP-glucuronosyltransferase (UGT) and cytochrome 450 (CYP) enzymes, but information on interactions with common anticonvulsive drugs is incomplete. We report a case series of five patients receiving adjunctive treatment with CBD who showed increases in brivaracetam (BRV) levels by 95% to 280%. Only two patients reported mild adverse events, leading to a reduction of BRV in one patient. One possible mechanism contributing at least partially to increasing BRV level is the inhibition of CYP2C19 by cannabidiol. Further pharmacokinetic studies are required to understand other possible mechanisms of brivaracetam-cannabidiol interaction. Copyright Wiley Periodicals, Inc. © 2019 International League Against Epilepsy

Case series
Grade 4- very low

Another problem of the regular smoking of C. sativa is the high THC level in the bloodstream, which can induce anxiety attacks, schizophrenia and precocious psychotic alterations in people who are genetically predisposed [16]. One study showed that the use of C. sativa is associated with higher susceptibility to infections and increased rates of head and neck cancer [17]. Those authors also reported that THC has immunomodulatory properties, by reducing the ability of macrophages to produce cytokines, limiting their capacity to recognize antigens, in turn weakening the cytolytic and proliferative response of the T lymphocytes and the production of antibodies by the B lymphocytes.

To degrade the BC, we used the same method described above. A solution of 7 μM BC in hexane was injected into CSS and this was repeated every 20 min for a period of 9 h, after which the hexane was removed with a rotary evaporator (40 °C) to obtain the sample BC degraded by the C. sativa smoke (BCCSS). The entire experiment was conducted at room temperature. Each cigarette consumed generated about 400 mL of smoke.

2.3. Kinetic analysis of degradation of BC by CSS

The antioxidant activity was determined by the ABTS• + free radical sequestration method, as described previously [18]. The sample of BCCSS was obtained as described in paragraph 2.4 and was diluted in ethanol.

The β-carotene (95% purity) was acquired from Sigma-Aldrich. The C. Sativa was supplied by the Judicial Office of the city of Limoeiro, state of Pernambuco, Brazil, after authorization by Judge José Claudionor da Silva Filho and by the Forensic Institute of Pernambuco, on the decision of its manager Dr. Luiz Carlos Soares da Silva. The experiment of degradation of BC by CSS was carried out in the Police Science Laboratory of Pernambuco.

To assess toxicity, we used the method previously reported [22] with some modifications. The culture of this crustacean was carried out in a plastic aquarium with 20 mg of A. salina cysts incubated in artificial brine (37.5 g of sea salt per liter of distilled water) under continuous aeration, to maintain an oxygen-saturated state, with constant artificial illumination (40-W light bulb) for 24 h for hatching. The test was run in triplicate with different sample concentrations (1000, 700, 500, 210, 100 and 50 μg/mL), with a final volume of 5 mL in each test tube. The negative control was a solution containing A. salina without the sample solutions. BCCSS samples were used, obtained as described in paragraph 2.4. Ten larvae were transferred to each tube and maintained under artificial lighting for 24 h. After this period, the living and dead larvae were counted. In bioactivity evaluation by brine shrimp bioassay, cytotoxic activity is considered weak when the LC50 is between 500 and 1000 μg/mL, moderate when the LC50 is between 100 and 500 μg/mL, and strong when the LC50 is between 0 and 100 μg/mL.